Lenvima, Kisplyx (lenvatinib) is a small molecule pharmaceutical. Lenvatinib was first approved as Lenvima on 2015-02-13. It is used to treat renal cell carcinoma and thyroid neoplasms in the USA. It has been approved in Europe to treat renal cell carcinoma and thyroid neoplasms. The pharmaceutical is active against vascular endothelial growth factor receptor 2 and vascular endothelial growth factor receptor 3. Lenvima's patents are valid until 2035-08-26 (FDA).
|Trade Name||Kisplyx, Lenvima|
|Indication||renal cell carcinoma, thyroid neoplasms|
|Drug Class||Tyrosine kinase inhibitors|